Endoscopic Submucosal Dissection of Early Gastric Cancer That Occurred in a Patient with Chronic Myelogenous Leukemia.
- Author:
Young HWANGBO
1
;
Jae Young JANG
;
Jaejun SHIM
;
Seok Ho DONG
;
Hyo Jong KIM
;
Byung Ho KIM
;
Young Woon CHANG
;
Rin CHANG
Author Information
1. Department of Internal Medicine, Kyunghee University School of Medicine, Seoul, Korea. mumock@freechal.com
- Publication Type:Case Report
- Keywords:
Gastric cancer;
Chronic myelogenous leukemia;
Multiple primary cancer;
Endoscopic submucosal dissection;
Imatinib
- MeSH:
Benzamides;
Eye;
Hemorrhage;
Humans;
Leukemia;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Middle Aged;
Philadelphia Chromosome;
Piperazines;
Pyrimidines;
Stomach Neoplasms;
Imatinib Mesylate
- From:Korean Journal of Gastrointestinal Endoscopy
2009;38(5):288-293
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Synchronous double malignancies of early gastric cancer and chronic myelogenous leukemia (CML) are very rare. There are few reports regarding the effect of the CML or imatinib on stomach cancer, and it is difficult to make a decision for the proper timing of treatment for early gastric cancer (EGC) in a patient with CML. A 56-year-old man was diagnosed with early gastric cancer. During the evaluation of his disease, he was also diagnosed as having Philadelphia chromosome positive chronic myleogenous leukemia. He started to take 400 mg of imatinib per day. Two weeks later, he underwent endoscopic submucosal dissection (ESD) for the early gastric cancer. Although there was a bleeding complication, complete resection was successfully performed. ESD is an effective treatment modality for EGC in CML patients, but physicians should keep a watchful eye for bleeding complications after the procedure. Further studies and more experience are needed to determine the proper timing of treatment for these patients.
